In several clinical trials, antibody company Micromet has demonstrated outstanding efficacy and safety of its bispecific BiTE antibodies which come with two binding sites: one for a cancer target and a second one for a T cell. As a result, T cells are recruited and guided directly to the tumor cell, initiating cancer cell death in a serial fashion.
Company News: Micromet Presents Updated Results From Phase 1 and Phase 2 Study of Blinatumomab
Monday, June 14, 2010
- Update Presented at the 15th Annual Congress of the European Hematology Association (EHA) -
Micromet, Inc. (NASDAQ: MITI) today announced updated clinical data from a Phase 1 and a Phase 2 trial, respectively, of its lead product blinatumomab (MT103). The data were presented at the 15th Annual Congress of the European Hematology Association (EHA) in Barcelona, Spain.
Company News: Micromet Announces Global Collaboration with Boehringer Ingelheim for Multiple Myeloma BiTE Antibody and Reports First Quarter 2010 Financial Results
Wednesday, May 5, 2010
Micromet, Inc. (Nasdaq: MITI) and Boehringer Ingelheim announced today that they have entered into a collaboration agreement for the research, development and commercialization of a new BiTE antibody for the treatment of multiple myeloma.
Despite recent advances in the treatment of multiple myeloma, the disease remains largely incurable. While the majority of patients initially respond to treatment, almost all of these patients will eventually relapse.
Company News: Micromet Achieves Milestone under BiTE Antibody Collaboration with Bayer Schering Pharma
Wednesday, April 21, 2010
Micromet, Inc. (NASDAQ: MITI) a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, announced today that it has achieved a milestone under its collaboration agreement with Bayer Schering Pharma AG. The milestone was triggered by Micromet’s achievement of pre-clinical proof of concept for a BiTE antibody for the treatment of solid tumors. For more information, please read the complete press release
Company News: Micromet Closes $80.5 Million Public Offering of Common Stock
Wednesday, March 17, 2010
Micromet, Inc. (NASDAQ: MITI) announced today the closing of its previously announced underwritten public offering and raises net proceeds of approximately $ 75.3 million, after deducting the underwriting discount and estimated offering expenses. For more information, please click here.
Company News: Micromet Reports Fourth Quarter and Full Year 2009 Financial Results
Thursday, March 4, 2010
Micromet, Inc. (NASDAQ: MITI), a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced its financial results for the fourth quarter and full year ended December 31, 2009. The Company also highlighted recent pipeline progress and outlined expected 2010 milestones.
Further details can be found at: www.micromet-inc.com
